United States

Celgene Corp (CELG.O)

CELG.O on Nasdaq

12:39pm EDT
Change (% chg)

$7.35 (+7.47%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for CELG.O


Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology... (more)


Beta: 1.74
Market Cap(Mil.): $76,279.04
Shares Outstanding(Mil.): 775.11
Dividend: --
Yield (%): --


  CELG.O Industry Sector
P/E (TTM): 41.32 44.78 33.70
EPS (TTM): 2.38 -- --
ROI: 9.79 2.97 13.98
ROE: 32.45 3.01 14.91

Celgene's Revlimid sales spark forecast raise, shares jump

U.S. biotechnology company Celgene Corp raised its profit and revenue forecast for the year after posting third-quarter results ahead of Wall Street estimates, lifted by higher demand for its flagship multiple myeloma drug, Revlimid.

11:16am EDT

UPDATE 3-Celgene's Revlimid sales spark forecast raise, shares jump

* Shares rise as much as 6.9 pct to $105.29 (Adds analyst comments, conf call details; updates shares)

11:15am EDT

BRIEF-Celgene says Q3 growth rate mainly volume driven - conf call

* Says q3 growth rate was predominantly volume driven: conf call

11:05am EDT

US STOCKS-Healthcare, tech stocks drive Wall Street higher

* Bristol-Myers, Celgene lead health stocks higher post results

9:56am EDT

BRIEF-Celgene Q3 adjusted earnings per share $1.58

* Celgene reports third quarter 2016 operating and financial results

7:39am EDT

Celgene quarterly revenue rises 28 percent as Revlimid shines

Oct 27 U.S. biotechnology company Celgene Corp reported a 28 percent jump in quarterly revenue, fueled by higher demand for its flagship multiple myeloma drug, Revlimid.

7:38am EDT

BRIEF-Celgene & Sage Bionetworks use apple researchkit for observational study

* Celgene Corporation and Sage Bionetworks announce technology collaboration to develop observational study using the apple researchkit framework

Oct 18 2016

BRIEF-Celgene & Agios collaborates with Abbott to develop diagnostic tests for leukemia

* Celgene and Agios announce collaborations with Abbott for diagnostic identification of IDH mutations in AML

Oct 12 2016

Amgen's multiple myeloma drug falls short in new-patient study

Amgen Inc said on Tuesday its multiple myeloma drug, Kyprolis, did not fare better than Takeda Pharmaceutical Co Ltd's older therapy Velcade in a study involving patients who had not yet been treated for the disease.

Sep 27 2016

UPDATE 3-Amgen's multiple myeloma drug falls short in new-patient study

* Amgen stock down about 1.2 pct (Adds comments from conference call, analysts, details)

Sep 27 2016


  Price Chg
Takeda Pharmaceutical Co Ltd (4502.T) ¥4,788 -16.00
Eisai Co., Ltd (4523.T) ¥6,785 -65.00
Johnson & Johnson (JNJ.N) $115.99 +1.43
Novartis AG (NOVN.S) CHF71.40 +0.20
Pfizer Inc. (PFE.N) $32.67 +0.27
Roche Holding Ltd. (ROG.S) CHF230.30 +3.80
Roche Holding Ltd. (RO.S) CHF233.90 +4.40
Merck & Co., Inc. (MRK.N) $61.76 +0.89
Sanofi SA (SASY.PA) €68.86 +0.75
AstraZeneca plc (AZN.L) 4,614.50p -162.50

Earnings vs. Estimates